Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
716 (USA) · Dr. Ito
consented 2013-02-01
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-15 (study day 43.0); relationship: PROBABLE
mild
assessed
Mild MALIGNANT FIBROUS HISTIOCYTOMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-19 (study day 19.0); relationship: NONE
mild
assessed
Mild MALIGNANT FIBROUS HISTIOCYTOMA — outcome: RECOVERED/RESOLVED; onset 2013-02-19 (study day 19.0); relationship: NONE
moderate
assessed
Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-15 (study day 43.0); relationship: PROBABLE
Data queries
No data queries.